

REMEDIUM LIFECARE LTD.

(Formerly known as "Roxy Exports Limited")

CIN: L24100MH1988PLC343805

601, Hyde Park, CTS No. 680, Saki Vihar Road
Sakinaka, Andheri (E), Mumbai - 400 072

info@remediumlifecare.com

+91-(22)-28505005



July 07, 2021

To,
Listing Compliance Department
BSE Limited
P. J. Tower, Dalal Street,
Mumbai - 400 001

Scrip Code: 539561 / REMLIFE

Sub: Outcome of the Board Meeting held on 07.07.2021

Dear Sir,

This is to inform you that the Board of Directors of the Company at its meeting held today, i.e. on July 07, 2021 has inter alia transacted the following business:

1. Approved the Unaudited Standalone Financial results for the quarter ended June 30, 2021.
2. Approved and taken on record the resignation of Mr. Nishant Phadtare from the position of Company Secretary and Compliance Officer of the Company w.e.f. closing of business hours on 07.07.2021.

Pursuant to Clause 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Unaudited Standalone Financial Results of the Company for the quarter ended June 30, 2021 together with the Limited Review Report of the Statutory Auditors in respect of the same.

The meeting of the Board of Directors of the company commenced at 4:00 pm and concluded at 5:00 pm.



We request you to kindly take the note of the above and update the same in your records.

Thanking you,

Yours faithfully,

For Remedium Lifecare Limited


Ashish Parkar
Chief Financial Officer



Encl: As above.

Taori Sandeep & Associates

CHARTERED ACCOUNTANTS

Br. Office: Flat No.201, Nav Sudhir CHS Ltd, 113, Tilak Nagar, M.G. Road No.6, Goregaon West.
Mumbai- 400 104. Mob- 7021416997, 07738364419 Email-cpatul14@gmail.com

Head Office: "Deepa - Lakshmi" 106, Kherapati Colony, Gwalior - 474002 (M.P.)

Independent Auditor's Review Report on Quarterly Unaudited Financial Results of Remedium Lifecare Limited (formerly known as Roxy Exports Limited) pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

To

**The Board of Directors of Remedium Lifecare Limited
(formerly known as Roxy Exports Limited)**

1. We have reviewed the accompanying statement of unaudited financial results ('the Statement') of **Remedium Lifecare Limited (formerly known as Roxy Exports Limited)** ('the Company') for the quarter ended 30th June, 2021 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended, including relevant circulars issued by the SEBI from time to time.
2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Taori Sandeep & Associates

CHARTERED ACCOUNTANTS

Br. Office: Flat No.201, Nav Sudhir CHS Ltd, 113, Tilak Nagar, M.G. Road No.6, Goregaon West.
Mumbai- 400 104. Mob- 7021416997, 07738364419 Email-cpatul14@gmail.com

Head Office: "Deepa - Lakshmi" 106, Kherapati Colony, Gwalior - 474002 (M.P.)

4. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For TAORI SANDEEP & ASSOCIATES

Chartered Accountants


FRN: 007414C



Atul Jain

Partner

M. No. 048920



Place: Mumbai

Date: July 7, 2021

UDIN: 21048920AAAACH5814

REMEDIUM LIFECARE LIMITED
(Formerly Known as "Roxy Exports Limited")
REDG. Office No. 601, Hyde Park, Saki-Vihar Road, Andheri (E), Mumbai — 400072.
Phone: 022-28505005
E-mail: info@remediumlifecare.com, Website - https://www.remediumlifecare.com;
CIN: L24100MH1988PLC343805

Statement of Standalone Unaudited Financial Results for the Quarter ended, 30th June 2021

(Rs. in Lakhs)

Particulars	Quarter Ended			Year Ended
	30th June, 2021	31st March, 2021	30th June, 2020	31st March, 2021
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
I. Revenue from Operations	13813.08	5585.48	22.36	9003.39
II. Other Income	0.00	0.20	0.00	0.20
III. Total Income (I +II)	13813.08	5585.68	22.36	9003.59
IV. Expenses				
Cost of Material Consumed	13708.22	5488.76	2.12	8773.94
Purchases of Stock-in-trade	0.00	0.00	0.00	0.00
Changes in inventories of finished goods, Work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00
Employee Benefits Expenses	3.26	7.80	6.65	18.80
Finance Costs	0.00	0.00	0.00	0.00
Depreciation and amortisation expenses	1.60	1.60	1.34	6.01
Other Expenses	54.79	41.76	10.74	139.56
Total Expenses (IV)	13767.87	5539.93	20.86	8938.31
V. Profit/(Loss) before exceptional items and tax (III- IV)	45.20	45.75	1.50	65.29
VI. Exceptional items	0.00	0.00	0.00	0.00
VII. Profit/(Loss) before tax (V-VI)	45.20	45.75	1.50	65.29
VIII. Tax Expense				
(1) Current tax	0.00	17.27	0.00	17.27
(2) Deferred tax	0.00	-0.04	0.00	-0.04
(3) Previous Year Tax	0.00	0.00	0.00	0.00
Total Tax	0.00	17.24	0.00	17.24
IX. Profit/(Loss) for the period from continuing operations (VII-VIII)	45.20	28.52	1.50	48.05
X. Profit/(Loss) from discontinued operations	0.00	0.00	0.00	0.00
XI. Tax expense of discontinued operations	0.00	0.00	0.00	0.00
XII. Profit/(Loss) from Discontinued operations (after tax) (X-XI)	0.00	0.00	0.00	0.00
XIII. Profit/(Loss) for the period (IX+XII)	45.20	28.52	1.50	48.05
XIV. Other Comprehensive Income	0.00	0.00	0.00	0.00
(A) (i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
(B) (i) Items that will be classified to profit or loss	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
XV. Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the Period)	45.20	28.52	1.50	48.05
XVI. Earnings per equity share (for continuing operation):				
(1) Basic	0.00	0.00	0.00	0.00
(2) Diluted	0.00	0.00	0.00	0.00
XVII. Earnings per equity share (for discontinued operation):				
(1) Basic	0.00	0.00	0.00	0.00
(2) Diluted	0.00	0.00	0.00	0.00
XVIII. Earnings per equity share (for discontinued & continuing operations)				
(1) Basic	0.00	0.00	0.00	0.00
(2) Diluted	0.00	0.00	0.00	0.00

Notes:

- The above results have been reviewed by Audit Committee and taken on record by the Board of Directors at its Meeting held on 7th July, 2021. The Statutory Auditors of the Company have carried out a limited review of the above financial results of the company for the quarter ended on June 30, 2021.
- The figures for the quarter ended 31st March, 2021 are the balancing figures between audited figures in respect of the full financial year and the unaudited published year to date figures up to 3rd Quarter of the respective financial year.
- The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IND AS), prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- The figures for the previous period/year have been regrouped/reclassified, wherever necessary, to conform to the current period/year classification
- Disclosure pursuant to Reg 33(1) (e) read with clause D Part A of Schedule IV of SEBI (LODR) Reg 2015

Disclosure related to new line of Business:

Net Sales -	Rs, 13,649.44 Lakh
Net Cost of Goods sold and Expenditure -	Rs, 13,604.23 Lakh
Net Profit -	Rs, 42.19 Lakh

For Remedium Lifecare Limited

VILAS
RAMKRISHNA
LOKHANDE

VILAS LOKHANDE
(Managing Director)
DIN : 01228041
Date: 07.07.2021
Place : Mumbai